glp 1 agonist comparison chart Currently available GLP-1 RAs Comparison between GLP-1 receptor agonists

In theory, that can help deliver oxygen and nutrients to damaged tissue

Parkinsons disease, characterized by dopaminergic neuronal loss in the substantia nigra leading to motor and non-motor symptoms, has also been linked to insulin resistance and impaired cerebral insulin signaling.128 GLP-1RAs and GLP-1/GIP dual-receptor agonists have demonstrated the capacity to enhance insulin sensitivity and exert antioxidant and anti-inflammatory effects in the brain.129 Preclinical studies in various PD animal models indicate that GLP-1RAs such as liraglutide, semaglutide, and lixisenatide promote dopamine synthesis and elevate striatal dopamine levels, thereby conferring neuroprotection to dopaminergic neurons.130132 The dual agonist telpor similarly exhibits neuroprotective effects by improving energy metabolism and inhibiting inflammatory pathways in PD models.126 Clinical trials have assessed the efficacy and safety of GLP-1RAs in PD patients with PD

Secondary brain injury (SBI) occurs after primary injury, with microglial activation occurring minutes after ICH

Glutathione infusion before and 3 days after primary angioplasty blunts ongoing NOX2-mediated inflammatory response